These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23963965)

  • 21. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder.
    Papakostas GI; Worthington JJ; Iosifescu DV; Kinrys G; Burns AM; Fisher LB; Homberger CH; Mischoulon D; Fava M
    Depress Anxiety; 2006; 23(3):178-81. PubMed ID: 16528701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial.
    Fornaro M; Martino M; Mattei C; Prestia D; Vinciguerra V; De Berardis D; De Pasquale C; Iasevoli F; Mungo S; Fornaro P
    Eur Neuropsychopharmacol; 2014 Aug; 24(8):1269-78. PubMed ID: 24842649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis.
    Weiner E; Ball MP; Buchholz AS; Gold JM; Evins AE; McMahon RP; Buchanan RW
    J Clin Psychiatry; 2012 Jan; 73(1):95-102. PubMed ID: 21535998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modafinil treatment in patients with seasonal affective disorder/winter depression: an open-label pilot study.
    Lundt L
    J Affect Disord; 2004 Aug; 81(2):173-8. PubMed ID: 15306145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL.
    Modell JG; Rosenthal NE; Harriett AE; Krishen A; Asgharian A; Foster VJ; Metz A; Rockett CB; Wightman DS
    Biol Psychiatry; 2005 Oct; 58(8):658-67. PubMed ID: 16271314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of bupropion hydrochloride extended-release versus escitalopram oxalate in Chinese patients with major depressive disorder: Results from a randomized, double-blind, non-inferiority trial.
    Shen Y; Zhao Q; Yu Y; Tan Y; Zhang H; Xu X; Wang Z; Li Y; Hu J; Zhong J; Li H
    J Affect Disord; 2019 Oct; 257():143-149. PubMed ID: 31301615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in Japan.
    Higuchi T; Kamijima K; Nakagome K; Itamura R; Asami Y; Kuribayashi K; Imaeda T
    Int Clin Psychopharmacol; 2016 Jan; 31(1):8-19. PubMed ID: 26513202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression.
    Cox LS; Patten CA; Niaura RS; Decker PA; Rigotti N; Sachs DP; Buist AS; Hurt RD
    J Gen Intern Med; 2004 Aug; 19(8):828-34. PubMed ID: 15242467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder.
    Herrera-Guzmán I; Gudayol-Ferré E; Lira-Mandujano J; Herrera-Abarca J; Herrera-Guzmán D; Montoya-Pérez K; Guardia-Olmos J
    Psychiatry Res; 2008 Jul; 160(1):72-82. PubMed ID: 18501971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
    J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
    Munizza C; Olivieri L; Di Loreto G; Dionisio P
    Curr Med Res Opin; 2006 Sep; 22(9):1703-13. PubMed ID: 16968574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized-controlled trials comparison with venlafaxine.
    Maneeton N; Maneeton B; Eurviriyanukul K; Srisurapanont M
    Drug Des Devel Ther; 2013; 7():1053-62. PubMed ID: 24101861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE; Franznick DA; Hollander SB; Fava M
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
    Jefferson JW; Pradko JF; Muir KT
    Clin Ther; 2005 Nov; 27(11):1685-95. PubMed ID: 16368442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
    Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
    J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults.
    Wilens TE; Spencer TJ; Biederman J; Girard K; Doyle R; Prince J; Polisner D; Solhkhah R; Comeau S; Monuteaux MC; Parekh A
    Am J Psychiatry; 2001 Feb; 158(2):282-8. PubMed ID: 11156812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study.
    Wilens TE; Haight BR; Horrigan JP; Hudziak JJ; Rosenthal NE; Connor DF; Hampton KD; Richard NE; Modell JG
    Biol Psychiatry; 2005 Apr; 57(7):793-801. PubMed ID: 15820237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.
    Evins AE; Cather C; Culhane MA; Birnbaum A; Horowitz J; Hsieh E; Freudenreich O; Henderson DC; Schoenfeld DA; Rigotti NA; Goff DC
    J Clin Psychopharmacol; 2007 Aug; 27(4):380-6. PubMed ID: 17632223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial.
    Bech P; Fava M; Trivedi MH; Wisniewski SR; Rush AJ
    Acta Psychiatr Scand; 2012 Apr; 125(4):342-8. PubMed ID: 22077211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.